Official Sections CTRMS ISVCA IPITA IPTA ISODP IRTA IXA SPLIT TID

COVID-19
CORONAVIRUS UPDATES

Lorem ipsum dolor sit amet consetetur sadipscing elitr sed diam nonumy eirmod tempor invidunt ut labore et dolore magna aliquyam erat.

TTS 2020 Virtual invites you to participate during a special symposium on COVID-19 and its impact on transplantation.

The Symposium will take place after the President’s Plenary on day one of the TTS 2020 Virtual Congress. For scheduling details please visit: tts2020.org/program

In response to the Covid-19 pandemic, The Transplantation Society has created this COVID-19 Dashboard to serve as a resource for transplant professionals to get up to date information about the pandemic.

The Covid-19 Committee is meeting multiple times a week, working together to address the needs of the international transplant community as the situation unfolds.

If you are a Transplant Professional and you have questions to ask the committee or, would like to contribute valuable information to the Dashboard - Kindly email This email address is being protected from spambots. You need JavaScript enabled to view it..

TTS Resources

Guidance on Coronavirus Disease 2019 (COVID-19) for Transplant Clinicians
This is the third update of Coronavirus Disease 2019 (COVID-19) Guidance from the TID Section of TTS. It is important to note that information about this disease and our understanding of this virus and its impact on transplantation is evolving rapidly so the guidance may change over time. We plan to regularly update the guidance as new information becomes available.
Ethical Issues in the COVID Era: ‘Doing the right thing’ depends on location, resources and disease burden
The transplant community is well-versed in ethical issues surrounding the allocation of scarce resources, but the COVID-19 pandemic has escalated moral dilemmas of transplantation far beyond simply allocation of limited donor organs. Emanuel et al. were unfortunately prophetic in their recent NEJM article addressing the ethical principles guiding medical decisions during the COVID-19 pandemic and the associated depletion of resources (1). Hospital and intensive care resources are becoming severely limited in high-transmission areas, influencing decisions about who should be transplanted and affecting the availability of donated organs (2). The risk of COVID-19 transmission to donors and recipients further alters such risk considerations. Pre-COVID-19 organ allocation schemes, which are complex, transparent and organ-specific, are by themselves insufficient to determine who should be transplanted under such conditions, particularly in resource-constrained areas.
Transplantation - The Impact of COVID-19 on the state of clinical and laboratory research globally in transplantation in May 2020
The impact of the COVID-19 pandemic is very wide and occupies almost every aspect of life across the world with the wave of direct health impacts cutting across each nation at different paces. The impact on the economies of all countries has been dramatic and has yet to become fully apparent. The effect of the pandemic on the health of transplant patients has been extensive with data published across a number of journals from both single centres and regional and national databases. It is becoming clear that transplant patients are more likely to catch SARSCov2 and when infected have a much increased mortality risk. Impact on clinical services, through reduction in ICU bed availability and decreased deceased organ donors, as well as diversion of clinical staff and other resources from transplantation, has led to dramatic decreases in clinical transplant activity. We have documented these impacts through the pages of Transplantation and through the COVID-19 Transplantation map established with the cooperation of The Transplantation Society (1,2). What has not yet been documented to any degree so far, is the impact on clinical and basic laboratory research in Transplantation. This round up of experiences from around the world shows substantial closure and diversion of effort from Transplantation research both in the clinic and in the laboratory with a future that is uncertain. Some countries and some centres have been more impacted than others. We hope by illuminating this feature of the pandemic we can assist in resuscitating research in our field as soon as compatible with the phases of the pandemic in each country.
Transplantation - Mortality rates in Transplant recipients infected with SARSCov2 and diagnosed as having COVID-19. April 2020
Transplantation Journal - COVID WORLD ROUNDUP - April 2020

Mortality rates in Transplant recipients infected with SARSCov2 and diagnosed as having COVID-19. April 2020

There has been a global assumption that transplant recipients would be particularly endangered by the current pandemic of Coronovirus. Data have however been quite sparse and the ability to create a global picture has been limited.  Case reports are now giving way to small case series in the literature. The Transplantation Journal has collected the following data from correspondents from around the world and offers it as a very limited and highly flawed view of what might be happening.
Data from New York centres has been supplied from New York and are presented separately as they provide the most comprehensive view of the increased risk of death for transplant recipients across the spectrum of organ transplant types. The story of a widespread tragedy in the field of Transplantation is not underestimating the current data. Careful inspection of the data could be seen to show two features:

  1. High mortality rates in the range of 15-30% for transplant recipients in the countries and regions with high incidences and high mortality rates in the general populations.
  1. Low incidence and no mortality for transplant recipients in low incidence countries, suggesting that transplant recipients may have heeded well the messages to isolate themselves from the virus.

Country

COVID pos

alive In ICU

Dead

Mongolia

0

0

0

New Zealand

0

0

0

India (5 States)

1

0

0

Denmark

2

0

1

Singapore

0

0

0

Hong Kong

1

0

0

Brazil

27

3

7

Korea

2

0

0

Australia

3

0

0

USA

9

1

0

Italy

20

4

5

Strasbourg

48

10

9

London

7

4

1

Totals

120

22

23

(All data reports above are at the time of reporting in April)

 

«HOT OFF THE PRESS» RECENT PUBLICATIONS IDENTIFIED BY TTS EDUCATION COMMITTEE ON COVID-19

June 17

Living donor liver transplants for sick recipients during COVID-19 pandemic- An experience from a tertiary center in India.

Verma, S.; Aleen Agarwal, S.; Chikkala, B. R.; Dey, R.; Singh, S.; Varma, S.; Yadav, V.; Das, D.; Goyal, S.; Pandey, V. K.; Nasa, V.; Madan, K.; Shweta, S.; Tarai, B.; Gupta, S.
American Journal of Transplantation. 2020;[record in progress]

The concerns in Living Donor Liver Transplant (LDLT) are that immunosuppressed recipients and healthy donors would be exposed to nosocomial SARS‐ CoV‐2 infection. However, as described in this paper from a tertiary center in India, as patients began to suffer and die; LDLT was allowed for those who were very sick, or had just recovered from a life threatening decompensation (high MELD/ CTP score) or had malignancy.


Coronavirus Disease (COVID-19) in Kidney and Liver Transplant Patients: A Single-Center Experience.

Aydincan Akdur, Emre Karakaya, Ebru H. Ayvazoglu Soy, Omar Alshalabi, Mahir Kirnap, Hande Arslan, Gaye Ulubay, Koray Hekimoglu, Gokhan Moray, Mehmet Haberal
Experimental and Clinical Transplantation (2020) 3: 270-274

This article included 583 transplant patients (509 kidney and 74 liver) who were screened at a single transplant center in Turkey between March 1 and May 1, 2020. 18 patients had respiratory symptoms and only one patient diagnosed with COVID-19.


COVID-19 in elderly kidney transplant recipients.

Marta Crespo, María José Pérez-Sáez, Dolores Redondo-Pachón, Laura Llinàs-Mallol, María Milagro Montero, Judith Villar, Carlos Arias-Cabrales, Anna Buxeda, Carla Burballa, SusanaVázquez, Thais López, Fátima Moreno, Marisa Mir, Sara Outón, Adriana Sierra, Silvia Collado, Clara Barrios, Eva Rodríguez, Laia Sans, Francesc Barbosa, Higini Cao, María Dolores Arenas, Roberto Güerri-Fernández, Juan Pablo Horcajada, Julio Pascual
American Journal of Transplantation 2020 doi: 10.1111/AJT.16096

This article describes 16 kidney transplant recipients over age of 65 with COVID-19. 33% showed renal graft dysfunction. Short-term fatality rate was 50% at a median time since admission of 3 days. Those who died were more frequently obese, frail and had underlying heart disease. Patients who died were more anemic, lymphopenic and showed higher D-dimer, C-reactive protein, and IL-6 at their first tests.


How should I manage immunosuppression in a kidney transplant patient with COVID-19? An ERA-EDTA DESCARTES expert opinion.

Umberto Maggiore, Daniel Abramowicz, Marta Crespo, Christophe Mariat, Geir Mjoen, Licia Peruzzi, Mehmet Sükrü Sever, Gabriel C Oniscu, Luuk Hilbrands, Bruno Watschinger on behalf of the DESCARTES Working Group of the ERA-EDTA

This article reviews previous published studies of kidney transplant recipients with COVID-19 and discusses current treatment options.


Rapid generation of neutralizing antibody responses in COVID-19 patients.

Mehul S. Suthar, Matthew G. Zimmerman, Robert C. Kauffman, Grace Mantus, Susanne L. Linderman, William H. Hudson, Abigail Vanderheiden, Lindsay Nyhoff, Carl W. Davis, Seyi Adekunle, Maurizio Affer, Melanie Sherman, Stacian Reynolds, Hans P. Verkerke, David N. Alter, Jeannette Guarner, Janetta Bryksin, Michael Horwath, Connie M. Arthur, Natia Saakadze, Geoffrey Hughes Smith, Srilatha Edupuganti, Erin M. Scherer, Kieffer Hellmeister, Andrew Cheng, Juliet A. Morales, Andrew S. Neish, Sean R. Stowell, Filipp Frank, Eric Ortlund, Evan Anderson, Vineet D. Menachery, Nadine Rouphael, Aneesh Mehta, David S. Stephens, Rafi Ahmed, John D. Roback, Jens Wrammert
Cell Reports Medicine. DOI: https://doi.org/10.1016/j.xcrm.2020.100040

This article reports a cross-sectional study of antibody responses to the receptor-binding domain (RBD) of the spike protein and virus neutralization activity in a cohort of 44 hospitalized COVID-19 patients. The RBD-specific binding data were further validated in a clinical setting with 231 PCR-confirmed COVID-19 patient samples. These findings have implications for understanding protective immunity against SARS-CoV-2, therapeutic use of immune plasma, and development of much-needed vaccines.


June 11

Effect of Convalescent Plasma Therapy on Time to Clinical Improvement in Patients With Severe and Life-threatening COVID-19: A Randomized Clinical Trial.

Ling Li, MD, PhD
JAMA. doi:10.1001/jama.2020.10044
Published online June 3, 2020.

This is an open-label, multicenter, randomized clinical trial performed in 7 medical centers in Wuhan, China. The trial included 103 participants with laboratory confirmed COVID-19 that was severe (respiratory distress and/or hypoxemia) or life-threatening (shock, organ failure, or requiring mechanical ventilation). Convalescent plasma in addition to standard treatment (n = 52) vs standard treatment alone (control) (n = 51), stratified by disease severity. There was no significant difference in 28-day mortality (15.7%vs 24.0%; OR, 0.65 [95%CI, 0.29-1.46]; P = .30. Convalescent plasma treatment was associated with a negative conversion rate of viral PCR at 72 hours in 87.2%of the convalescent plasma group vs 37.5% of the control group (OR, 11.39 [95%CI, 3.91-33.18]; P < .001).Convalescent plasma therapy added to standard treatment, compared with standard treatment alone, did not result in a statistically significant improvement in time to clinical improvement within 28 days.


COVID-19 in liver transplant recipients: preliminary data from the ELITA/ELTR registry.

Luca S Belli, Christophe Duvoux, Vincent Karam, Rene Adam, Valentin Cuervas-Mons, Luisa Pasulo, Carmelo Loinaz, Federica Invernizzi, Damiano Patrono, Sherrie Bhoori, Olga Ciccarelli, Maria Cristina Morelli, Lluis Castells, Victor Lopez-Lopez, Sara Conti, Costantino Fondevila, Wojchiech Polak
Lancet Gastroenterol Hepatol. 2020 Jun 4 

This is a report about the course and management of SARS-CoV-2 infection in 10 liver transplant recipients from a single center in Northwestern Italy in the period March-April 2020. Overall mortality was 20%, whereas Covid-related mortality was 10%.


Early Outcomes of Outpatient Management of Kidney Transplant Recipients with Coronavirus Disease 2019.

Husain SA, Dube G, Morris H, Fernandez H, Chang JH, Paget K, Sritharan S, Patel S, Pawliczak O, Boehler M, Tsapepas D, Crew RJ, Cohen DJ, Mohan S.Clin J Am Soc Nephrol. 2020 May 18:CJN.05170420

The study describes an early cohort of outpatient kidney transplant recipients with known or suspected coronavirus disease 2019, of which many had symptomatic resolution without requiring hospitalization.


COVID-19 and kidney transplantation: an Italian Survey and Consensus.

Vistoli F, Furian L, Maggiore U, Caldara R, Cantaluppi V, Ferraresso M, Zaza G, Cardillo M, Biancofiore G, Menichetti F, Russo A, Turillazzi E, Di Paolo M, Grandaliano G, Boggi U; Italian National Kidney Transplantation Network; the Joint Committee of the Italian Society of Organ Transplantation and the Italian Society of Nephrology.J Nephrol. 2020 Jun 3. doi: 10.1007/s40620-020-00755-8. Online ahead of print.

Based on the Italian experience, the authors discuss the reasons for the changes in kidney transplantation activity during the COVID-19 pandemic in Western countries. They also provide working recommendations for the organization and management of kidney transplantation under these conditions. Overall, 60 recipients tested positive for SARS-CoV2 infection, 57 required hospitalization, 17 were admitted to the ICU, and 11 died.


The Innate Immune System: Fighting on the Front Lines or Fanning the Flames of COVID-19?

Julia L. McKechnie, Catherine A. Blish
Cell Host Microbe. 2020 May 20 doi: 10.1016/j.chom.2020.05.009 [Epub ahead of print]
PMCID: PMC7237895

In this review, the authors discuss what is known about the role of the innate immune system during SARS-CoV-2 infection, suggest directions for future studies, and evaluate proposed COVID-19 immunomodulating therapeutics.


The effect of large-scale anti-contagion policies on the COVID-19 pandemic

Hsiang, S., Allen, D., Annan-Phan, S. et al.
Nature (2020). https://doi.org/10.1038/s41586-020-2404-8

This article compiles new data on 1,717 local, regional, and national non-pharmaceutical interventions deployed in the ongoing pandemic across localities in China, South Korea, Italy, Iran, France, and the United States. In the absence of policy actions, the authors estimated that early infections of COVID-19 exhibit exponential growth rates of roughly 38% per day. It is estimated that across these six countries, interventions prevented or delayed on the order of 62 million confirmed cases, corresponding to averting roughly 530 million total infections.


June 4

Mortality and pulmonary complications in patients undergoing surgery with perioperative SARS-CoV-2 infection: an international cohort study.

COVIDSurg Collaborative*
LANCET May 29, 2020 https://doi.org/10.1016/S0140-6736(20)31182-X

This is an international, multicentre, cohort study at 235 hospitals in 24 countries included all patients undergoing surgery who had SARS-CoV-2 infection confirmed within 7 days before or 30 days after surgery. This article analyzes 1128 patients who had surgery between Jan 1 and March 31, 2020, of whom 835 (74·0%) had emergency surgery and 280 (24·8%) had elective surgery. SARS-CoV-2 infection was confirmed preoperatively in 294 (26·1%) patients. 30-day mortality was 23·8%. Pulmonary complications occurred in 51·2% of the patients; 30-day mortality in these patients was 38·0%. The authors reported risk factors for mortality.


Strategies for Liver Transplantation during the SARS CoV‐2 Outbreak Preliminary Experience from a Single Center in France.

Xavier Muller et al.
American Journal of Transplantation First published: 31 May 2020
https://doi.org/10.1111/ajt.16082

This article reports strategies and preliminary results in liver transplantation during the peak of the SARS‐CoV‐2 pandemic from a single‐center in France. The authors performed 10 successful liver transplantations during the peak of the pandemic with a short median intensive care unit stay (2,5 days), benchmark post‐transplant morbidity and no occurrence of SARS‐CoV‐2 infection during follow‐up.


Epidemiology, clinical course, and outcomes of critically ill adults with COVID-19 in New York City: a prospective cohort study.

Matthew J Cummings, Matthew R Baldwin, Darryl Abrams, Samuel D Jacobson, Benjamin J Meyer, Elizabeth M Balough, Justin G Aaron,
Jan Claassen, LeRoy E Rabbani, Jonathan Hastie, Beth R Hochman, John Salazar-Schicchi, Natalie H Yip, Daniel Brodie, Max R O’Donnell
LANCET May 19, 2020
https://doi.org/10.1016/S0140-6736(20)31189-2

This article reviewed 1150 adults who were admitted to between March 2 and April 1, 2020, with laboratory-confirmed COVID-19, of which 257 (22%) were critically ill. As of April 28, 2020, 39% patients had died, 79% patients received invasive mechanical ventilation, 31% received renal replacement therapy. Older age, chronic heart and lung disease, high IL6 and D-dimer levels were associated with mortality.


Anakinra for severe forms of COVID-19: a cohort study.

Thomas Huet, Hélène Beaussier, Olivier Voisin, Stéphane Jouveshomme, Gaëlle Dauriat, Isabelle Lazareth, Emmanuelle Sacco, Jean-Marc Naccache, Yvonnick Bézie, Sophie Laplanche, Alice Le Berre, Jérôme Le Pavec, Sergio Salmeron, Joseph Emmerich, Jean-Jacques Mourad, Gilles Chatellier, Gilles Hayem
Lancet Rheumatol 2020 Published Online May 29, 2020
https://doi.org/10.1016/S2665-9913(20)30164-8

This article reports 52 consecutive patients in the anakinra group and 44 historical patients who were identified in the Groupe Hospitalier Paris Saint-Joseph COVID cohort study from March 24 to April 6, 2020. Admission to the ICU for invasive mechanical ventilation or death occurred in 13 (25%) patients in the anakinra group and 32 (73%) patients in the historical group (hazard ratio [HR] 0・22 [95% CI 0・11–0・41; p<0・0001). The treatment effect of anakinra remained significant in the multivariate analysis (HR 0・22 [95% CI 0・10–0・49]; p=0・0002).


Antibody responses to SARS-CoV-2 in patients with COVID-19.

Quan-Xin Long et al.
Nature Medicine
https://doi.org/10.1038/s41591-020-0897-1

This article reports acute antibody responses to SARS-CoV-2 in 285 patients with COVID-19. Within 19 days after symptom onset, 100% of patients tested positive for antiviral immunoglobulin-G (IgG). Seroconversion for IgG and IgM occurred simultaneously or sequentially. Both IgG and IgM titers plateaued within 6 days after seroconversion. Serological testing may be helpful for the diagnosis of suspected patients with negative RT–PCR results and for the identification of asymptomatic infections.

 


May 27

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19.

Maximilian Ackermann, M.D., Stijn E. Verleden, Ph.D., Mark Kuehnel, Ph.D., Axel Haverich, M.D., Tobias Welte, M.D., Florian Laenger, M.D., Arno Vanstapel, Ph.D., Christopher Werlein, M.D., Helge Stark, Ph.D., Alexandar Tzankov, M.D., William W. Li, M.D., Vincent W. Li, M.D., Steven J. Mentzer, M.D., and Danny Jonigk, M.D.
DOI: 10.1056/NEJMoa2015432

This article examined lungs from 7 autopsies to try to better understand the pathophysiology of the progressive respiratory failure that leads death in Covid-19 infection. In Covid-19 patients the histological finding was a diffuse alveolar damage with perivascular T-cell infiltration, associated to severe endothelial, intracellular virus and disrupted cell membranes, together with widespread thrombosis and microangiopathy. Covid-19 patients had also intussusceptive angiogenesis, which it is a distinctive from equally severe influenza virus infection.


Remdesivir for the Treatment of Covid-19— Preliminary Report.

J.H. Beigel, K.M. Tomashek, L.E. Dodd, A.K. Mehta, B.S. Zingman, A.C. Kalil, E. Hohmann, H.Y. Chu, A. Luetkemeyer, S. Kline, D. Lopez de Castilla, R.W. Finberg, K. Dierberg, V. Tapson, L. Hsieh, T.F. Patterson, R. Paredes, D.A. Sweeney, W.R. Short, G. Touloumi, D.C. Lye, N. Ohmagari, M. Oh, G.M. Ruiz‑Palacios, T. Benfield, G. Fätkenheuer, M.G. Kortepeter, R.L. Atmar, C.B. Creech, J. Lundgren, A.G. Babiker, S. Pett, J.D. Neaton, T.H. Burgess, T. Bonnett, M. Green, M. Makowski, A. Osinusi, S. Nayak, and H.C. Lane, for the ACTT-1 Study Group Members*
DOI: 10.1056/NEJMoa2007764

This is a double-blind, randomized, placebo-controlled trial of intravenous remdesivir in adults hospitalized with Covid-19 with evidence of lower respiratory tract involvement. Patients were randomly assigned to receive either remdesivir (200 mg loading dose on day 1, followed by 100 mg daily for up to 9 additional days) or placebo for up to 10 days. Preliminaryresults from the 1059 patients (538 assigned to remdesivir and 521 to placebo) indicated that those who received remdesivir had a median recovery time of 11 days (95% confidence interval [CI],9 to 12), as compared with 15 days (95% CI, 13 to 19) in those who received placebo. The Kaplan- Meier estimates of mortality by 14 days were 7.1% with remdesivir and 11.9% with placebo (hazard ratio for death, 0.70; 95% CI, 0.47 to 1.04).


Hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19: a multinational registry analysis.

Mandeep R Mehra, Sapan S Desai, Frank Ruschitzka, Amit N Patel
Lancet. Published on lime May 22, 2020
https://doi.org/10.1016/ S0140-6736(20)31180-6

This article did a multinational registry analysis of the use of hydroxychloroquine or chloroquine with or without a macrolide for treatment of COVID-19. 96032 patients (mean age 53·8 years, 46·3% women) with COVID-19 were hospitalised during the study period and met the inclusion criteria. Of these, 14 888 patients were in the treatment groups (1868 received chloroquine, 3783 received chloroquine with a macrolide, 3016 received hydroxychloroquine, and 6221 received hydroxychloroquine with a macrolide) and 81 144 patients were in the control group. Each of these drug regimens was associated with decreased in-hospital survival and an increased frequency of ventricular arrhythmias when used for treatment of COVID-19.


Imbalanced Host Response to SARS-CoV-2 Drives Development of COVID-19.

Daniel Blanco-Melo, Benjamin E. Nilsson-Payant, Wen-Chun Liu, Skyler Uhl, Daisy Hoagland, Rasmus Møller, Tristan X. Jordan, Kohei Oishi, Maryline Panis, David Sachs, Taia T. Wang, Robert E. Schwartz, Jean K. Lim, Randy A. Albrecht, and Benjamin R. tenOever
Cell 181, 1–10, May 28, 2020 ª 2020 Elsevier Inc.
https://doi.org/10.1016/j.cell.2020.04.026

This article documented an in-depth analysis of the transcriptional response to SARS-CoV-2 compared with other respiratory viruses. Cell and animal models of SARS-CoV-2 infection, in addition to transcriptional and serum profiling of COVID-19 patients, consistently revealed a unique and inappropriate inflammatory response. This response is defined by low levels of type I and III interferons juxtaposed to elevated chemokines and high expression of IL-6.


Targets of T cell responses to SARS-CoV-2 coronavirus in humans with COVID-19 disease and unexposed individuals.

Alba Grifoni, Daniela Weiskopf, Sydney I. Ramirez, Jose Mateus, Jennifer M. Dan, Carolyn Rydyznski Moderbacher, Stephen A. Rawlings, Aaron Sutherland, Lakshmanane Premkumar, Ramesh S. Jadi, Daniel Marrama, Aravinda M. de Silva, April Frazier, Aaron Carlin, Jason A. Greenbaum,
CELL 11420
DOI: https://doi.org/10.1016/j.cell.2020.05.015

Using HLA class I and II predicted peptide ‘megapools’, circulating SARS-CoV-2-specific CD8+ and CD4+ T cells were identified in ~70% and 100% of COVID-19 convalescent patients, respectively. CD4+ T cell responses to spike, the main target of most vaccine efforts, were robust and correlated with the magnitude of the anti-SARS-CoV-2 IgG and IgA titers. The authors detected SARS-CoV-2-reactive CD4+ T cells in ~40-60% of
unexposed individuals, suggesting cross-reactive T cell recognition between circulating ‘common cold’ coronaviruses and SARS-CoV-2.


Safety, tolerability, and immunogenicity of a recombinant adenovirus type-5 vectored COVID-19 vaccine: a dose-escalation, open-label, non-randomised, first-in-human trial.

Feng-Cai Zhu, Yu-Hua Li, Xu-Hua Guan, Li-Hua Hou, Wen-Juan Wang, Jing-Xin Li, Shi-Po Wu, Bu-Sen Wang, Zhao Wang, Lei Wang, Si-Yue Jia, Hu-Dachuan Jiang, Ling Wang, Tao Jiang, Yi Hu, Jin-Bo Gou, Sha-Bei Xu, Jun-Jie Xu, Xue-Wen Wang, Wei Wang, Wei Chen
Lancet May 2020
https://doi.org/10.1016/ S0140-6736(20)31208-3

This is a dose-escalation, single-centre, open-label, non-randomised, phase 1 trial of an Ad5 vectored COVID-19 vaccine in Wuhan, China. 108 participants (51% male, 49% female; mean age 36·3 years) were recruited and received the low dose (n=36), middle dose (n=36), or high dose (n=36) of the vaccine. ELISA antibodies and neutralising antibodies increased significantly at day 14, and peaked 28 days post-vaccination. Specific T-cell response peaked at day 14 post-vaccination.


May 20

Organ procurement and transplantation during the COVID-19 pandemic.

Loupy A, Aubert O, Reese PP, Bastien O, Bayer F, Jacquelinet C.
Lancet. 2020 May 11. pii: S0140-6736(20)31040-0. doi: 10.1016/S0140-6736(20)31040-0. [Epub ahead of print] No abstract available.
PMID: 32407668

This article documented a 90.6% reduction in deceased donor transplantations since the COVID-19 outbreak in France and 51.1% in the USA, respectively.


Pathological inflammation in patients with COVID-19: a key role for monocytes and macrophages.

Merad M, Martin JC.
Nat Rev Immunol. 2020 May 6. doi: 10.1038/s41577-020-0331-4. [Epub ahead of print] Review.
PMID: 32376901

This article describes potentially pathological roles of macrophages during SARS- CoV-2 infection and discusses ongoing and prospective therapeutic strategies to modulate macrophage activation in patients with COVID-19.


COVID-19 in kidney transplant recipients.

Nair V, Jandovitz N, Hirsch JS, Nair G, Abate M, Bhaskaran M, Grodstein E, Berlinrut I, Hirschwerk D, Cohen SL, Davidson KW, Dominello AJ, Osorio GA, Richardson S, Teperman LW, Molmenti EP.
Am J Transplant. 2020 Apr 29. doi: 10.1111/ajt.15967. [Epub ahead of print]
PMID: 32351040

This article reports 30% mortality and 50% acute kidney injury in 10 kidney transplant recipients.


Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York.

Haberman R, Axelrad J, Chen A, Castillo R, Yan D, Izmirly P, Neimann A, Adhikari S, Hudesman D, Scher JU.
N Engl J Med. 2020 Apr 29. doi: 10.1056/NEJMc2009567. [Epub ahead of print] No abstract available.
PMID: 32348641

This article identified 86 patients with immune-mediated inflammatory disease who had either confirmed (59 patients) or highly suspected (27 patients) symptomatic Covid-19 infection. 62 of 86 (72%) were receiving biologics or Janus kinase (JAK) inhibitors, and the overall incidence of hospitalization was 16%.


Effective treatment of severe COVID-19 patients with tocilizumab.

Xu X, Han M, Li T, Sun W, Wang D, Fu B, Zhou Y, Zheng X, Yang Y, Li X, Zhang X, Pan A, Wei H. Proc Natl Acad Sci U S A. 2020 Apr 29. pii: 202005615. doi: 10.1073/pnas.2005615117. [Epub ahead of print]
PMID: 32350134

This is a retrospective, uncontrolled study of 21 patients with severe COVID-19 who received treatment with the IL-6 blocker tocilizumab. Within 24 hours of starting tocilizumab therapy, fevers and elevated C-reactive protein levels resolved, and levels of IL-6 and other proinflammatory cytokines declined. All patients subsequently were discharged alive.


Characteristics and Outcomes of Recipients of Heart Transplant With Coronavirus Disease 2019.

Latif F, Farr MA, Clerkin KJ, Habal MV, Takeda K, Naka Y, Restaino S, Sayer G, Uriel N.
JAMA Cardiol. 2020 May 13. doi: 10.1001/jamacardio.2020.2159. [Epub ahead of print]
PMID: 32402056

This article describes case series of 28 patients who had received heart transplant in a large academic center. The mortality rate was 25% and 76% had evidence of myocardial injury. Mycophenolate mofetil was discontinued in 16 patients (70%), and 6 (26%) had a reduction in the dose of their calcineurin inhibitor. Treatment of COVID-19 included hydroxychloroquine (78%), high-dose corticosteroids (47%), and interleukin 6 receptor antagonists (26%).


May 13

This week's selection made by: Enver Akalin, Marlies Reinders, Pablo Uva, Nithya Krishnan, Manisha Sahay, Shannon Grappe and Annmarie Liapakis

Acute Kidney Injury in COVID-19: Emerging Evidence of a Distinct Pathophysiology.

Batlle D, Soler MJ, Sparks MA, Hiremath S, South AM, Welling PA, Swaminathan S; COVID-19 and ACE2 in Cardiovascular, Lung, and Kidney Working Group.
J Am Soc Nephrol. 2020 May 4.

This article emphasizes that AKI can be a severe complication of COVID-19 and the importance of assessing, defining, and reporting the course of AKI is highlighted.


Immediate impact of COVID-19 on transplant activity in the Netherlands.

de Vries APJ, Alwayn IPJ, Hoek RAS, van den Berg AP, Ultee FCW, Vogelaar SM, Haase-Kromwijk BJJM, Heemskerk MBA, Hemke AC, Nijboer WN, Schaefer BS, Kuiper MA, de Jonge J, van der Kaaij NP, Reinders MEJ.
Transpl Immunol. 2020 May 1:101304.

This article describes the enormous impact of COVID-19 on transplant activity in the Netherlands. There was a significant decrease in organ donation numbers affecting all organ transplant services and detrimental effect on transplantation numbers in children with end-organ failure. The paper also describes ongoing efforts focus on mitigation of not only primary but also secondary harm of the pandemic and to find right definitions and momentum to restore the transplant programs.


Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions.

Elens L, Langman LJ, Hesselink DA, Bergan S, Moes DJAR, Molinaro M, Venkataramanan R, Lemaitre F.
Ther Drug Monit. 2020 Apr 15.

This article inform the clinicians about the potential interactions of experimental COVID-19 treatments with immunosuppressive drugs used in transplantation. Recommendations regarding therapeutic drug monitoring and dose adjustments in the context of COVID-19 are provided.


Utilization of deceased donors during a pandemic: An argument against using SARS-CoV-2 positive donors.

Shah MB, Lynch RJ, El-Haddad H, Doby B, Brockmeier D, Goldberg DS.
Am J Transplant. 2020 May 5

This article presents a review of the current literature that details the potential negative consequences of COVID-19 positive donors. The authors concluded that COVID-19 infection should continue to remain a contraindication for donation, as has been the initial response of donation and transplantation societies.


Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.

Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, Labella A, Manson D, Kubin C, Barr RG, Sobieszczyk ME, Schluger NW.
N Engl J Med. 2020 May 7. 

This observational study involving 1446 patients with Covid-19 who had been admitted to the hospital documented that hydroxychloroquine administration was not associated with either a greatly lowered or an increased risk of the composite end point of intubation or death. 


May 6

This week's selection made by: Enver Akalin, Marcelo Cantarovich and Medhat Askar

Acute Kidney Injury in COVID-19: Emerging Evidence of a Distinct Pathophysiology.

Batlle D, Soler MJ, Sparks MA, Hiremath S, South AM, Welling PA, Swaminathan S; COVID-19 and ACE2 in Cardiovascular, Lung, and Kidney Working Group.
J Am Soc Nephrol. 2020 May 4.

This article emphasizes that AKI can be a severe complication of COVID-19 and the importance of assessing, defining, and reporting the course of AKI is highlighted.


Immediate impact of COVID-19 on transplant activity in the Netherlands.

de Vries APJ, Alwayn IPJ, Hoek RAS, van den Berg AP, Ultee FCW, Vogelaar SM, Haase-Kromwijk BJJM, Heemskerk MBA, Hemke AC, Nijboer WN, Schaefer BS, Kuiper MA, de Jonge J, van der Kaaij NP, Reinders MEJ.
Transpl Immunol. 2020 May 1:101304.

This article describes the enormous impact of COVID-19 on transplant activity in the Netherlands. There was a significant decrease in organ donation numbers affecting all organ transplant services and detrimental effect on transplantation numbers in children with end-organ failure. The paper also describes ongoing efforts focus on mitigation of not only primary but also secondary harm of the pandemic and to find right definitions and momentum to restore the transplant programs.


Pharmacologic treatment of transplant recipients infected with SARS-CoV-2: considerations regarding therapeutic drug monitoring and drug-drug interactions.

Elens L, Langman LJ, Hesselink DA, Bergan S, Moes DJAR, Molinaro M, Venkataramanan R, Lemaitre F.
Ther Drug Monit. 2020 Apr 15.

This article inform the clinicians about the potential interactions of experimental COVID-19 treatments with immunosuppressive drugs used in transplantation. Recommendations regarding therapeutic drug monitoring and dose adjustments in the context of COVID-19 are provided.


Utilization of deceased donors during a pandemic: An argument against using SARS-CoV-2 positive donors.

Shah MB, Lynch RJ, El-Haddad H, Doby B, Brockmeier D, Goldberg DS.
Am J Transplant. 2020 May 5

This article presents a review of the current literature that details the potential negative consequences of COVID-19 positive donors. The authors concluded that COVID-19 infection should continue to remain a contraindication for donation, as has been the initial response of donation and transplantation societies.


Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19.

Geleris J, Sun Y, Platt J, Zucker J, Baldwin M, Hripcsak G, Labella A, Manson D, Kubin C, Barr RG, Sobieszczyk ME, Schluger NW.
N Engl J Med. 2020 May 7. 

This observational study involving 1446 patients with Covid-19 who had been admitted to the hospital documented that hydroxychloroquine administration was not associated with either a greatly lowered or an increased risk of the composite end point of intubation or death. 


April 29

This week's selection made by: Enver Akalin, Milagros Samaniego-Picota and Gabriel Gondolesi. The article tites are hyperlinks

Pharmacologic Treatments for Coronavirus Disease 2019 (COVID-19): A Review.

Sanders JM, Monogue ML, Jodlowski TZ, Cutrell JB.
JAMA. 2020 Apr 13. doi: 10.1001/jama.2020.6019. [Epub ahead of print]
PMID: 32282022

This is a review regarding pharmacologic treatment of patients with COVID-19. Currently, there is no evidence from randomized clinical trials that any potential therapy improves outcomes inpatients with either suspected or confirmed COVID-19.


Presenting Characteristics, Comorbidities, and Outcomes Among 5700 Patients Hospitalized With COVID-19 in the New York City Area.

Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW; and the Northwell COVID-19 Research Consortium, Barnaby DP, Becker LB, Chelico JD, Cohen SL, Cookingham J, Coppa K, Diefenbach MA, Dominello AJ, Duer-Hefele J, Falzon L, Gitlin J, Hajizadeh N, Harvin TG, Hirschwerk DA, Kim EJ, Kozel ZM, Marrast LM, Mogavero JN, Osorio GA, Qiu M, Zanos TP.
JAMA. 2020 Apr 22. doi: 10.1001/jama.2020.6775. [Epub ahead of print]
PMID: 32320003

Clinical outcomes were assessed for 2634 patients who were discharged or had died at the study end point. During hospitalization, 373 patients (14.2%) (median age, 68 years [IQR, 56-78]; 33.5% female) were treated in the intensive care unit care, 320 (12.2%) received invasive mechanical ventilation, 81 (3.2%) were treated with kidney replacement therapy, and 553 (21%) died. Mortality for those requiring mechanical ventilation was 88.1%. 


Covid-19 and Kidney Transplantation.

Akalin E, Azzi Y, Bartash R, Seethamraju H, Parides M, Hemmige V, Ross M, Forest S, Goldstein YD, Ajaimy M, Liriano-Ward L, Pynadath C, Loarte-Campos P, Nandigam PB, Graham J, Le M, Rocca J, Kinkhabwala M.
N Engl J Med. 2020 Apr 24. doi: 10.1056/NEJMc2011117. [Epub ahead of print] No abstract available.
PMID: 32329975

Montefiore Medical Center reported clinical outcomes of 36 consecutive adult kidney transplant recipients. 28 patients (78%) required hospital admission. Twenty-seven (96%) of hospitalized patients had imaging findings of viral pneumonia, 11(39%) required mechanical ventilation and 6 (21%) required renal replacement therapy. Mortality was 10 (28%) overall, 7 (64%) in intubated patients, with a median follow-up of 21 days (range 14-28).


Management Of Patients On Dialysis And With Kidney Transplant During SARS-COV-2 (COVID-19) Pandemic In Brescia, Italy.

Alberici F, Delbarba E, Manenti C, Econimo L, Valerio F, Pola A, Maffei C, Possenti S, Piva S, Latronico N, Focà E, Castelli F, Gaggia P, Movilli E, Bove S, Malberti F, Farina M, Bracchi M, Costantino EM, Bossini N, Gaggiotti M, Scolari F; Brescia Renal COVID Task Force.
Kidney Int Rep. 2020 Apr 4. doi: 10.1016/j.ekir.2020.04.001. [Epub ahead of print] Review.
PMID:32292866

Italian experience in 20 kidney transplant recipients with COVID-19 pneumonia documented a fast progression in more than 75% of their patients with 25% mortality during a median follow-up of 7 days.


Early Impact of COVID-19 on Transplant Center Practices and Policies in the United States.

Boyarsky BJ, Chiang TP, Werbel WA, Durand CM, Avery RK, Getsin SN, Jackson KR, Kernodle AB, Van Pilsum Rasmussen SE, Massie AB, Segev DL, Garonzik-Wang JM.
Am J Transplant. 2020 Apr 13. doi: 10.1111/ajt.15915. [Epub ahead of print]
PMID: 32282982

This article reports the early impact of COVID-19 on transplant Center Practices and Policies in the US. Complete suspension of living-donor kidney transplant activity was reported by 71.8%, and living-donor liver transplant activity by 67.7%. Suspension of deceased-donor transplant activity was less frequent with restrictions for kidney donors in 84% and for liver donors by 73%, associated with the regional incidence of COVID-19.


Clinical Best Practice Advice for Hepatology and Liver Transplant Providers During the COVID-19 Pandemic: AASLD Expert Panel Consensus Statement.

Fix OK, Hameed B, Fontana RJ, Kwok RM, McGuire BM, Mulligan DC, Pratt DS, Russo MW, Schilsky ML, Verna EC, Loomba R, Cohen DE, Bezerra JA, Reddy KR, Chung RT.
Hepatology. 2020 Apr 16. doi: 10.1002/hep.31281. [Epub ahead of print]
PMID: 32298473

In this article, the AASLD expert panel propose detailed guidelines for diagnosis and management of COVID-19 in patients with chronic liver disease and liver transplant recipients including donor and recipient selection recommendations during the pandemic.


COVID-19 in Solid Organ Transplant Recipients: Initial Report from the US Epicenter.

Pereira MR, Mohan S, Cohen DJ, Husain SA, Dube GK, Ratner LE, Arcasoy S, Aversa MM, Benvenuto LJ, Dadhani D, Kapur S, Dove LM, Brown RS, Rosenblatt RE, Samstein B, Uriel N, Farr MA, Satlin M, Small CB, Walsh T, Kodiyanplakkal RP, Miko BA, Aaron JG, Tsapepas DS, Emond JC, Verna EC.
Am J Transplant. 2020 Apr 24. doi: 10.1111/ajt.15941. [Epub ahead of print]
PMID: 32330343

This article reports 90 transplant recipients (46 were kidney recipients, 17 lung, 13 liver, 9 heart and 5 dual-organ transplants) at 2 centers in New York. Among the 68 hospitalized patients, 12% required non-rebreather and 35% required intubation. Sixteen patients died (18% overall, 24% of hospitalized, 52% of ICU) and 37 (54%) were discharged.


COVID-19 in solid organ transplant recipients: a single-center case series from Spain.

Fernández-Ruiz M, Andrés A, Loinaz C, Delgado JF, López-Medrano F, San Juan R, González E, Polanco N, Folgueira MD, Lalueza A, Lumbreras C, Aguado JM.
Am J Transplant. 2020 Apr 16. doi: 10.1111/ajt.15929. [Epub ahead of print]
PMID: 32301155

This article reports preliminary experience with 18 SOT (kidney [44.4%], liver [33.3%] and heart [22.2%]) recipients diagnosed with COVID-19. The mortality rate was 27.8%.

Interactive Maps

Upcoming Webinars

June 18 - Clinicopathological Conference (CPC) - Combined Medical-Surgical Grand Rounds

Clinicopathological Conference (CPC) - Combined Medical-Surgical Grand Rounds
Thursday, June 18th, 2020 - 8 am - 9 am Eastern Standard Time

Click to attend

A 66-Year-Old Liver Transplant

Recipient with COVID-19

  • Jay A. Fishman, M.D., Transplant Infectious Diseases, Massachusetts General Hospital, United States
  • Matthew B. Roberts, M.B., B.S., Transplant Infectious Diseases, Massachusetts General Hospital, United States
  • Eric W. Zhang, M.D., Thoracic Imaging and Intervention, Radiology, Massachusetts General Hospital, United States
  • Deepali Kumar, M.D. Transplant Infectious Diseases, University of Toronto, Canada
  • Hans H. Hirsch, M.D., MSc.., Transplantation & Clinical Virology,, Biomedicine Infectious Diseases, University Hospital Basel, Switzerland
  • Umberto Maggiore, M.D. Transplant Nephrology, University of Parma, Italy

Registries & Surveys

Below is a list of registries. We do not endorse any specific registry over another however to avoid duplication please submit your data to only one center.
CareDx’ - International COVID-19 Solid Organ Transplant Registry
CareDx’ Caring for COVID-19 Transplant Patients: International Registry
COVID-19 Infections in Children

The Pediatric Infectious Disease Society through the PIDTRAN network of pediatric ID practitioners is collecting ALL COVID-19 cases in Pediatrics in the US including those with and without immunocompromising conditions. 

We encourage all pediatrics groups to work with their infectious disease colleagues to report each case only once.

We invite you/your center to participate. We are asking you to contribute de-identified information about any COVID-19 case in pediatric patients, inpatient or outpatient, diagnosed or treated at your center. 

This survey is for ALL pediatric patients less than 21 years of age in the USA, including:

  • General Pediatric patients, with or without other co-morbidities
  • Immunocompromised pediatric patients
  • Transplant  and cellular therapy recipients

To submit a case via the electronic survey forms, click here or copy and paste the following url: redcap.stjude.org/surveys/?s=37F8JCEWR8

What you need to know:

  • St. Jude Children's Research Hospital IRB has approved this study and has determined that other sites providing non-HIPAA identifiable clinical data for this project are NOT considered to be engaged in human subjects research. Your role in the project does NOT require local IRB approval at your site, but please refer to your local policies and procedures. (please see attached documentation that can be shared with your local IRB if needed.)
  • This is an initial survey for the first 7 days of COVID-19 illness. A follow-up survey forms should be completed once the patient has reached Day 28 post Covid-19 diagnosis. We will send you an email with the link to complete the follow-up survey forms once you have submitted the initial survey.
  • We hope that individuals within each institution will work together so that cases are only entered once.
  • Sites will be asked to record the REDCap assigned subject ID for each patient they submit. This subject ID will be available on the electronic survey. We have attached a log to track to use as a tool for tracking patients; however, you may use whatever tracking method you prefer. This log is not to be shared with anyone outside of your site. Please maintain your patient tracking linking the patient to the REDCap ID until notified that the study has been completed. 
  • We encourage you to share this invitation with your colleagues at other institutions!

Please contact This email address is being protected from spambots. You need JavaScript enabled to view it. with any questions.

Shared on behalf of the PIDSTRAN team and Gabriela Maron (St. Jude Children's Research Hospital).

Lara Danziger-Isakov, MD, MPH
Professor of Pediatrics
Director, Immunocompromised Host Infectious Diseases
Cincinnati Children's Hospital Medical Center

COVID-19 SOLID ORGAN TRANSPLANTATION STUDY GROUP SURVEY
The survey has been designed by researchers of Fondazione Policlinico Universitario A.Gemelli, IRCCS, Rome and it is promoted by several national and international scientific societies. There are more than 1300 participants from 62 nations all over the world and 518 individual registrations to the study group. We thank all of you for participating to the survey on COVID-19 & Solid Organ Transplant.
SPLIT-TTS/NASPGHAN Pediatric Hepatology and Pediatric Liver/Intestinal Transplantation COVID registry  

The Society of Pediatric Liver Transplantation (SPLIT), a section of TTS, and the North American Society of Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) have partnered to create a secure and de-identified online pediatric registry (for patients under the age of 21 years). Our intention is to collect and disseminate the experience of our community to better understand the clinical presentation, natural history and long-term outcomes in our hepatology and liver and intestinal transplant population. We are requesting all clinicians worldwide to report all cases of COVID -19 in children with chronic liver diseases (still with native liver), listed for pediatric liver/intestine transplantation, or have undergone liver and/or intestinal transplantation.  

We encourage you to complete this form even if the patient is in the middle of their COVID-19 course. This allows for timely dissemination back to our community. A weekly summary of COVID cases will be reported on the SPLIT COVID listserv, the NASPGHAN GI listserv and the NASPGHAN COVID website.   

To submit a case, please use this link or copy and paste the following url: https://is.gd/naspghansplitliversurvey  

Thank you to everyone in our community that is coming together at this time and for your efforts to serve our hepatology and transplant patients and support each other. Sincerely,

  • Mohit Kehar, Pediatric Gastroenterologist and Hepatologist, Queens University
  • Mercedes Martinez, Chair of the NASPGHAN Hepatology Committee and Medical Director of Intestinal Transplantation, Columbia University
  • Noelle Ebel, Transplant Hepatologist, Stanford University
  • Steven Lobritto, Chair of the SPLIT Quality Improvement and Clinical Care Committee, Medical Director of Pediatric Liver Transplantation, Columbia University
  • Vicky Ng, SPLIT President and Medical Director of Pediatric Liver Transplantation, University of Toronto  

This study has been granted REB/IRB clearance according to the recommended principles of Queen's University and Columbia University.

The International Database on Organ donation and Transplantation – COVID19

SARS-CoV-2 infection has been a challenge for health systems worldwide, causing a dramatic consumption of resources to cope with this pandemic caused by this recently identified virus. Solid information about SARS-CoV-2 (from a pathophysiological, clinical and therapeutic point of view) is scarce. On many occasions, these questions have been answered based on available knowledge from similar viruses such as SARS-CoV and MERS.

Due to the potential severity of this disease and the absence of current tools able to definitively modify its natural history, many are the ongoing research works that have been started since the description of the first case of COVID-19. Currently, our clinical practice in this type of infection is based on data especially from retrospective studies whose scientific power is questionable and which, on many occasions, provide contradictory messages.

These handicaps associated with the management and knowledge of COVID-19 extend, even with a greater lack of knowledge, to the population of recipients of a solid organ transplant (SOT) and to organ donation protocols, which have been adapted (in occasions drastically) to this new scenario. However, again, the data that supports these protocols and the available evidence on the management of organ donation and the recipient of a SOT are, likewise, of little scientific solidity.

As a result of this absence of solid evidence that allows for a significant improvement in the management of this risk population, The International Database on Organ donation and Transplantation – COVID19 (IDOTCOVID) has been designed. The present database tries to exhaustively collect the demographic, clinical, analytical and therapeutic data that of SOT recipients with COVID-19 and, afterwards, to extrapolate large-scale conclusions to provide reliable information and, more importantly, to guide in a solid way the future management of this population.

One of the main objectives of this project is the development of a tool that helps in the management of immunosuppression and the treatment of COVID19 infection in SOT recipients.

To achieve this, the following objectives have been designed to be developed in stages and progressively:

  1. Creation of an international database that includes all SOT recipient patients with COVID19 infection (confirmed or suspected);
  2. Inclusion of different clinical and analytical data with recognized prognostic factor in the general population;
  3. Inclusion of treatment data, including management of immunosuppression and clinical outcomes;
  4. Development of a Machine Learning algorithm that can assist the scientific community in updating their treatment management and immunosuppression protocols in this high-risk population;
University of Washington - COVID-19 in SOT Registry

COVID 19 in Solid Organ Transplant: Initial Report.


Step 1: Download and read the following required PDF document:
200403-UW-registry.pdf

Step 2: Access the registry page:
Click here to access

Global Resources

Global Alliance of Eye Bank Associations (GAEBA)
COVID-19 and Ocular Tissue Donation
HLA COVID-19
A centralized resource designed to support and combine efforts underway to study the association between HLA and COVID-19 infection and symptoms.
International Society For Heart And Lung Transplantation
COVID-19: Information for Transplant Professionals
International Liver Transplantation Society
Dedicated COVID-19 PageWebsite
Useful LinksWebsite
Video - COVID-19 and transplantation by ILTS ID and Liver Transplantant SIG, worldwide update on COVID-19 status by Vanguard Committee COVID-19 – The State of Affairs in Individual Countries across the Globe, presented by ILTS Vanguard Committee membersVideo
ISN - Recommendations for the Novel Coronavirus 2019 Epidemic: Kidney Patients, Health Care Professionals & Family/Caregivers
The International Society of Nephrology has put together this page to provide the global nephrology community on updates on the current global novel Coronavirus (COVID-19) pandemic.
Notify Library
RECOMMENDATIONS FOR EPIDEMIC DISEASE OCCURRENCE›SARS-CoV-2
Pediatric Heart Transplant Society (PHTS)
COVID-19 Resources for heart failure and transplant families including:
FAQs , For Children with Solid Organ Transplant or Heart Failure
What Parents Should Know - Check out everything you need to know when it comes to keeping your loved one safe during this pandemic! Why am I Staying Home?
World Health Organization - COVID-19 Updates and Videos

WHO YouTube Channel with daily updates and live press briefings
Click here to visit


Main COVID-19 Page
Click here to visit


World Health Organization - Country & Technical Guidance
A vast amount of resources including:
  • Critical preparedness, readiness and response actions for COVID-19
  • National laboratories
  • Risk communication and community engagement
  • Early investigation protocols
  • Naming the coronavirus disease (COVID-19)
  • Country-level coordination, planning, and monitoring
  • Clinical care
  • Operational support and logistics
  • Virus origin/Reducing animal-human transmission
  • Humanitarian operations, camps and other fragile settings
  • Surveillance, rapid response teams, and case investigation
  • Infection protection and control / WASH
  • Guidance for schools, workplaces & institutions
  • Points of entry / mass gatherings
  • Health workers
  • Maintaining Essential Health Services and Systems
World Marrow Donor Association
Huge resource page on COVID-19 - Impact on Registry Operations
Innovations in dealing with shortages
GlobalA Doctor Explains How to Make the Safest Face Mask
A doctor explains how to make the safest face mask. This is a safe face mask that if built properly should be donated to your local emergency services. It utilizes a HEPA filter, which is much, much better than a cotton mask.
Website
Can DIY Masks Protect Us from Coronavirus?
DIY masks to protect against from viruses sounds like a crazy idea. Data shows masks work incredibly well, and they’re also really cheap. Surgical masks cost a few pennies, and they’re capable of filtering out 80% of particles down to 0.007 microns (14 times smaller than the coronavirus).
Video: making a make-shift face shield using a surgical mask and plastic sheet
GlobalDIY N95 Face Mask | No Sew + Printable Template | Coronavirus | Covid-19
Note - This mask is not intended to replace a N95 mask. It will not protect you at the same level, but it is better than nothing
Website
GlobalHome-Made N95 Mask
Note - This mask is not intended to replace a N95 mask. It will not protect you at the same level, but it is better than nothing
Website
GlobalHongkongers make reusable fabric masks as Covid-19 epidemic leads to shortages and sky-high pricesPlay Video
GlobalInstructional video for sewing a child sized mask (COVID-19)
Note - This mask is not intended to replace a N95 mask. It will not protect you at the same level, but it is better than nothing
Website
GlobalInstructional video for sewing the Olson mask (COVID-19)
Learn how to sew a face mask with a filter pocket to insert filter material into the middle of the mask. Find the full sewing tutorial and free PDF pattern download here:
https://leahday.com/pages/how-to-make-a-face-mask-free-pattern
Note - This mask is not intended to replace a N95 mask. It will not protect you at the same level, but it is better than nothing. UPDATE - The PDF pattern has been updated to include tie instructions as well as elastic. I know most stores are out of thin elastic so I've updated the downloadable PDF pattern to use shoelaces to tie the mask to your face. New UPDATE - The PDF pattern has been updated again to include a child sized mask. One size fits all ages. I've also included washing, filter, and frequently asked questions to the pattern too. Please share this video and free sewing pattern. Please make masks and contact your local medical centers to learn where you can donate masks. Don't forget the VA hospitals, nursing homes, urgent care, and Hospice.
Website

Regional Updates & Resources

Africa
Southern AfricanSouthern African Transplantation Society
Position Statement and Patient Information
Website
AlgeriaMinistry of Health
Coronavirus COVID-19 page
Website
EthiopiaEthiopian Public Health InstituteWebsite
KenyaMinistry of HealthWebsite
LibyaGovernment websiteWebsite
MaliMalian Ministry of HealthWebsite
MoroccoMinistry of Health
COVID Page
Website
NigeriaApril 7 - COVID-19 Sub-Saharan Africa Update
NigeriaCentre for Disease Control (NCDC)
Coronavirus information
Website
NigeriaCOVID-19 Updates from the Federal Government of Nigeria
Coronavirus information
Website
South AfricaDepartment of Health
COVID-19 Corona Virus South African Resource Portal
Website
South AfricaGovernment of South Africa
The National Coronavirus Command Council has decided to enforce a nation-wide lockdown for 21 days with effect from midnight on Thursday 26 March.
Website
South AfricaSouth African Ministry of Health
Recent public presentation on the virus epidemiology
Play Video
South AfricaSouth African Tissue Bank Association
Position Statement
Website
South AfricaTransplantation Journal March Update
SudanFederal Ministry of HealthWebsite
TunisiaMinistère de la santé publique
Coronavirus COVID-19 page
Website
UgandaMinistry of HealthWebsite
Asia
ChinaGuidelines for organ donation and transplantation in China during the outbreak of new coronavirus pneumonia
(adopted on February 23, 2020) . This article (available in english and simplified Chinese) will be published in the Journal of Organ Transplant, No. 11, 2020, no. 179-184 (published on 15 March). Author: Chinese Medical Association Organ Transplant Association.
Download PDF in Orginal Language (simplified Chinese)
PDF
ChinaHong Kong - Transplantation Journal April 6 Update

Submitted by Nancy Kwan Man

ChinaHong Kong - Transplantation Journal April 8 Update

Submitted by Dr Maggie Ma (Vice President of HKST) on behalf of the Hong Kong Society of Transplantation


Kidney

(DDKT)

12

 

(LDKT)

1

Heart

2

Lung

2



DDKT: deceased donor kidney transplantation; LDKT : living donor kidney transplantation; DDLT: deceased donor liver transplant; LDLT: living donor liver transplantation

ChinaHong Kong - Transplantation Journal March Update
ChinaShanghai - Transplantation Journal - April 4 2020 Update
ChinaWuhan - Transplantation Journal March Update
ChinaWuxi - Transplantation Journal - April 4 2020 Update
IndiaGovernment of India
COVID-19 Update page
Website
IndiaGovernment of India
April 14 - PM Narendra Modi's address to the nation on COVID-19
Play Video
IndiaIndian Society of Transplantation (ISOT)
ISOT Transplant Specific Guidelines During COVID-19 Outbreak
PDF
IndiaMumbai - Transplantation Journal April 6 Update

Submitted by Shrirang Bichu, Bombay Hospital, Mumbai

IndiaNorth West - Transplantation Journal March Update
IndiaSouth - Transplantation Journal March Update
IndonesiaBadan Nasional Penanggulangan Bencana
Website Resmi Gugus Tugas Percepatan Penanganan COVID-19
Website
IndonesiaMinistry of Health
Coronavirus information
Website
IndonesiaNational Disaster Management Authority
COVID-19 Accelerated Handling Task Force Website
Website
JapanCabinet Secretariat
Coronavirus information - Japan
Website
JapanJapan Ministry of Health, Labor and Welfare
Coronavirus advisory information
Website
JapanMinistry of health press releasesWebsite
JapanTransplantation Journal March Update
KazakhstanGovernment websiteWebsite
KyrgyzstanMinistry of Health
website
Website
MalaysiaMinistry of Health
Coronavirus information
Website
MongoliaGovernment of Mongolia
COVID-19 updates (In Mongolian)
Website
MongoliaUlaanbaatar - Transplantation Journal March Update
NepalNepal Ministry of Health and Population
COVID-19 updates
Website
PakistanMain Government Page
Includes COVID-19 Updates
Website
PakistanNational Institute of Health (NIH)
COVID-19 Update page
Website
Papua New GuineaNational Department of Health
CORONAVIRUS DISEASE 2019 (COVID-19) OUTBREAK
Website
PhilippinesDepartment of Health
COVID-19 Update page
Website
SingaporeTransplantation Journal March Update
Singapore Ministry of Health
April 14 - Singapore remains in "critical situation" amid rise in COVID-19 cases: Health Minister
Play Video
Singapore Ministry of Health
Updates on local situation
Website
Singapore Prime Minister's Office, Singapore
April 14 - PM Lee Hsien Loong's Intervention at the Special ASEAN Summit on COVID-19
Play Video
South KoreaMinistry of health
Guidance for self-quarantine patients
Website
South KoreaMinistry of health
Briefing of Central Disaster and Safety Countermeasure Headquarters on COVID-19
Website
South KoreaTransplantation Journal March Update
TaiwanTaiwan Centers for Disease Control
Coronavirus information
Website
ThailandMinistry of Public’s Health
English-language COVID-19 page for updates on the situation in Thailand
Website
UzbekistanGovernment of Uzbekistan
Ministry of Health of the Republic of Uzbekistan
Website
VietnamMinistry of Health
Coronavirus information
Website
Europe
EuropeERA-EDTA - useful information on COVID-19 in renal patients including transplant recipients.
COVID-19: Information on Registry Initiatives
Website
EuropeEuropean Centre for Disease Prevention and Control
Coronavirus disease 2019 (COVID-19) and supply of substances of human origin in theEU/EEA
PDF
EuropeEuropean Centre for Disease Prevention and Control
Novel coronavirus disease 2019 (COVID-19)pandemic: increased transmission in the EU/EEAand the UK–sixth update
PDF
EuropeEuropean Centre for Disease Prevention and Control
The COVID-19 pandemic is rapidly evolving, and outbreak investigations are ongoing. ECDC is closely monitoring this outbreak, providing risk assessments, public health guidance, and advice on response activities to EU Member States and the EU Commission.
Website
EuropeEuropean Commission
Coronavirus response - Joint statement of the Members of the European Council (March 26 )
Website
EuropeEuropean Society for Blood and Marrow Transplantation (EBMT)
EBMT recommendation on: CORONAVIRUS DISEASE COVID-19
PDF
EuropeEuropean Society of TransplantationWebsite
EuropePolicy EurotransplantWebsite
AustriaFederal Ministry for Social Affairs, Health, Care and Consumer Protection
Coronavirus information - Austria
Website
AustriaPublic Health Agency of Austria
COVID update page
Website
BelgiumBelgian Federal Government
Coronavirus: reinforced measures
Website
BulgariaMinistry of Health
Information (Bulgarian only) for citizens and medical professionals
Website
CroatiaCroatian Institute of Public Health
Coronavirus information
Website
CroatiaGovernment of the Republic of Croatia
COVID-19 Epidemic update
Website
Czech RepublicMinistry of Health
Current incidence of COVID-19 in the Czech Republic
Website
Czech RepublicOffice of the Government
Coronavirus updates
Website
DenmarkDanish Health Authority
Help and information - Questions and Answers on the Corona Virus COVID-19
Website
DenmarkTransplantation Journal March Update
EnglandLondon - Transplantation Journal March Update
FinlandFinnish Institute for Health and Welfare
Coronavirus Information Page
Website
FranceAgence de Ia biomedecine
Mise a jour des recommandations concernant I'utilisation d'organes et de tissus preleves chez des donneurs a risque d'infection par Ie virus SARS-CoV-2- STADE 3 de I'epidemie
PDF
FranceGouvernement français
Coronavirus information - France
Website
FranceManagement of SARS-CoV-2 infection in adult solid organ transplant patients (In French)
April 2 - 14 page PDF Document produced by the Société Francophone de Transplantation (SFT), Société Francophone de Néphrologie, Dialyse et Transplantation (SFNDT) and Groupe Infection et Immunodépression, Société de pathologie infectieuse de langue française (SPILF).
PDF
FranceMinistry of Health
"in French"
Website
FranceParis - Kidney - Transplantation Journal March Update
FranceParis - Liver - Transplantation Journal March Update
FranceStrasbourg - Transplantation Journal March Update
GermanyMinistry of Health
COVID-19 Update page
Website
GermanyRegensburg - Transplantation Journal - April 7 2020 Update
GermanyTransplantation Journal March Update
GreeceNational Organization of Public Health
Coronavirus information - Greece
Website
HungaryGovernment of Hungary
Coronavirus information
Website
IrelandGovernment of Ireland
On this page you can view the latest information on how Ireland is responding to cases of COVID-19.
Website
ItalyMinestero della salud
Aggiornamento delle misure di prevenzione della trasmissione dell'infezione da nuovo Coronavirus (SARS-CoV-2) in Italia attraverso il trapianto di organi, tessuti e cellule.
PDF
ItalyMinistero della Salute
Coronavirus information - Italy
Website
MoldovaMinistry of Health, Labour and Social Protection
Coronavirus information
Website
NetherlandsNational Institute for Public Health and the Environment
Official information on COViD-19 in the Netherlands
Website
NetherlandsTransplantation Journal March Update
NetherlandsTransplantation policy in the NetherlandsWebsite
NorwayHealth Norway
Coronavirus information - Norway
Website
PolandApril 19 Update on COVID-19

This update was prepared in cooperation with Prof. Maciej Kosieradzki (President of Polish Union of Transplant Medicine) and Prof. Jarosław Czerwiński (Medical Director of Polish Transplant Coordinating Center Poltransplant.

PolandGovernment of Poland
The latest information about coronavirus
Website
PortugalDirectorate-General of Health
Help and information - Coronavirus (COVID-19)
Website
PortugalMinistério da Saúde
Coronavirus information
Website
RomaniaDepartment for Emergency Situation
Coronavirus information - Romania
Website
RomaniaMinisterul Afacerilor Interne
Help and information - Coronavirus updates
Website
RussiaMinistry of Health of the Russian Federation
Information about the new coronavirus infection
Website
RussiaRussian Federal Service for Surveillance on Consumer Rights Protection and Human Wellbeing (Rospotrebnadzor)
Coronavirus infection prevention
Website
SerbiaMinistry of Health
Coronavirus information
Website
SerbiaMinistry of Health
Coronavirus updates - Serbia
Website
SlovakiaPublic Health Authority
COVID update page
Website
SloveniaSlovenija-transplant
Institute for transplantation of organs and tissues of the Republic of Slovenia
Website
SpainCOVID-19 IN SPAIN AND ITS IMPACT UPON DONATION AND TRANSPLANTATION
Beatriz Domínguez-Gil, Elisabeth Coll, Organización Nacional de Trasplantes, Madrid, Spain

Transplantation Journal Update
Copyright © 2020 Wolters Kluwer Health, Inc. Unauthorized reproduction of this article is prohibited.

SpainMinistry of Health
Help and information - Coronavirus information - Spain
Website
SpainOrganización Nacional de Trasplantes (ONT)
April 13 Update - Spanish recommendations on organ donation and transplantation (ENG)
PDF
SpainTransplantation Journal March Update
SwedenPublic Health Agency of Sweden
COVID-19 Update page
Website
SwedenSwedish Civil Contingencies Agency
Official information on the novel corona virus
Website
SwitzerlandFederal Office of Public Health
Coronavirus information - Switzerland
Website
SwitzerlandSwissTransplant
Fact sheet concerning donors
PDF
SwitzerlandTransplantation Journal March Update
UkraineMinistry of health of Ukraine
Coronavirus information - Ukraine
Website
United KingdomNHS
Coronavirus condition overview - United Kingdom
Website
United KingdomNHS Blood and Transplant
COVID 19 Advice for Specialist Nurses Organ Donation and Specialist Requestors
PDF
United KingdomNHS Blood and Transplant
COVID-19: Clinical Advice
Website
United KingdomUK Government
Coronavirus (COVID-19): what you need to do
Website
United KingdomUK NHS
Advice for Clinicians
Website
United KingdomUniversity of Liverpool -- COVID-19 Drug Interaction
Prescribing Resources: The Liverpool Drug Interaction Group (based at the University of Liverpool, UK), in collaboration with the University Hospital of Basel (Switzerland) and Radboud UMC (Netherlands), have produced various materials in PDF format to aid the use of experimental agents in the treatment of COVID-19.
Website
Latin America
ArgentinaMinistry of Health
Information, recommendations of the Ministry of Health of the Nation and prevention measures (in spanish)
Website
ArgentinaSADI/INCUCAI/SAT Commission on Infections in Solid Organ Transplantation
In Spanish
PDF
BrazilMinistry of Health
Coronavirus information - Brazil
Website
BrazilTransplantation Journal April 6 Update
ChileMinistry of Health
Nuevo Coronavirus COVID-19 (Chile)
Website
ColombiaMinistry of Health
COVID Information page
Website
Costa RicaCosta Rica Ministry of Health
Coronavirus information
Website
CubaMinisterio de Salud Pública en Cuba
COVID update page
Website
EcuadorMinistry of Public Health
Coronavirus information
Website
GuatemalaMinistry of Public Health
COVID update page
Website
GuyanaMinistry of Public Health
COVID update page
Website
HondurasSecretaría de Salud
COVID update page
Website
MexicoGovernment of Mexico - Health Secretary
Coronavirus - Mexico
Website
NicaraguaMinisterio de Salud
COVID update page
Website
PanamaMinistry of Health
Coronavirus information
Website
ParaguayMinistry of Health
COVID Page
Website
PeruMinistry of Health
information on preventing COVID-19 transmission
Website
SurinameNational Crisis Portal
COVID update (in Dutch)
Website
UruguayMinistry of Public Health
COVID update page
Website
Middle East
IranHealth Department
COVID19 (Farsi)
Website
IranTransplantation Journal April 6 Update

Submitted by Amir Kasraianfard,  Mohssen Nassiri-Toosi, Ali Jafarian
Tehran University of Medical Sciences, Tehran, Iran

IsraelMinistry of Health
Official information of the Israeli Ministry of Health on the coronavirus
Website
IsraelThe Government of Israel
Israel's emergency web portal on covid-19
Website
JordanMinistry of Health
COVID19 (Arabic)
Website
KuwaitMinistry of Health
COVID-19 Update Website
Website
KuwaitUpdate on COVID-19

Kuwait is a small country with a population of 4 million. The present situation as of today is as follows:

LebanonApril 7 Update
Read More
OmanMinistry of Health
COVID19 (Arabic)
Website
QatarQatar ministry of health
COVID-19 page
Website
Saudi ArabiaSaudi Ministry of Health
COVID19 (Arabic)
Website
Saudi ArabiaTransplantation and COVID-19 Update
SyriaUpdate on COVID-19
TurkeyAnkara - Transplantation Journal April Update

Turkey update 04 April 2020

Submitted by Mehmet Haberal, Baskent University, Ankara


Turkey update March 2020

Submitted by Mehmet Haberal, Baskent University, Ankara

TurkeyGovernment of Turkey
COVID-19 Update page
Website
TurkeyUpdate on COVID-19

March 19 - Regarding Turkey, the number of confirmed cases are 1236 with 30 deaths.

UAEAbu Dhabi Department of Health
updates on COVID-19
Website
UAEDubai Health Authority
updates on COVID-19
Website
UAEUAE Ministry of Health and Prevention
updates on COVID-19
Website
North America
CanadaCanadian Blood Services
COVID-19 information
Website
CanadaCanadian Blood Services
COVID-19: Update on organ donation and transplantation services
Website
CanadaCanadian Society of Transplantation
COVID-19: Update
Website
CanadaGovernment of Canada
COVID-19 updates, prevention and risks, symptoms and treatment, travel advice and financial response
Website
CanadaGovernment of Canada
Canada COVID-19 Situational Awareness Dashboard
Website
CanadaHealth Canada
Coronavirus disease (COVID-19) information page
Website
CanadaMontreal - Transplantation Journal March Update
CanadaPublic Health Agency of Canada
Coronavirus disease (COVID-19): Outbreak update
Website
CanadaToronto - Transplantation Journal March Update
CanadaVaccines and treatments for COVID-19: List of all COVID 19 clinical trials authorized by Health Canada
Currently, the treatment of COVID-19 includes supportive care and treatment of any secondary infections, such as pneumonia. There are no drugs or vaccines approved, but there are now 20 clinical trials authorized in Canada with diagnostic equipment, supportive care and/or treatments for COVID-19.
Website
United StatesAmerican Association For The Study Of Liver Diseases
Clinical Insights For Hepatology And Liver Transplant Providers During The COVID-19 Pandemic
PDF
United StatesAmerican Association of Tissue Banks (AATB)
The AATB Physicians Council Issues Donor Screening and Deferral Recommendations to Tissue Bank Medical Directors Related to the Novel Coronavirus (2019-nCoV) Outbreak
PDF
United StatesAmerican Association of Tissue Banks (AATB)
Covid-19 Update
PDF
United StatesAmerican Medical Association
COVID-19 (2019 novel coronavirus) resource center for physicians
PDF
United StatesAmerican Medical Association.
COVID-19 (2019 novel coronavirus) resource center for physicians
Website
United StatesAmerican Society of Transplant Surgeons
COVID-19 Strike Force - Guidance for Organ Retrieval 
Website
United StatesAmerican Society of Transplantation (AST)
Covid-19 Resources for the Transplant Community
PDF
United StatesAmerican Society of Transplantation (AST)
The AST's Infectious Disease Community of Practice has received queries from transplant and donation colleagues regarding the novel coronavirus (2019-nCoV). The following FAQs were developed with input of members from both the organ donation and transplantation communities to relay information on the current state of knowledge.
PDF
United StatesAST COVID-19 Resources for Transplant CommunityWebsite
United StatesBaltimore - Transplantation Journal April 4, Update

Submitted by Daniel Brennan, ohns Hopkins University School of Medicine, Baltimore

United StatesCenters for Disease Control and Prevention
Interim Additional Guidance for Infection Prevention and Control Recommendations for Patients with Suspected or Confirmed COVID-19 in Outpatient Hemodialysis Facilities
Website
United StatesCenters for Disease Control and Prevention
CDC and dialysis units
Website
United StatesCOVID-19 FAQs For Children with Solid Organ Transplant or Heart failure
The Starzl Network for Excellence in Pediatric Transplantation and the Advanced Cardiac Therapies Improving Outcomes Network (ACTION) has developed an FAQ for pediatric transplant patients and their families.
PDF
United StatesEast Coast - Transplantation Journal March Update
United StatesEye Bank Association of America (EBAA)
CoronavirusDisease 2019(COVID-19) and Eye Tissue Donation
PDF
United StatesFood and Drug Administration (FDA)
Important Information for Human Cell, Tissue, or Cellular or Tissue-based Product (HCT/P) Establishments Regarding the 2019 Nove
PDF
United StatesFood and Drug Administration (FDA)
Important Information for Blood Establishments Regarding the NovelCoronavirus Outbreak
PDF
United StatesFood and Drug Administration (FDA)
Safety Alert on use of Fecal Microbiota for Transplantation and additional safety protections on SARS-CoV-2 and COVID19
PDF
United StatesMid-West - Transplantation Journal March Update
United StatesNew York - Transplantation Journal March Update
United StatesOrgan Procurement and Transplantation Network (OPTN)
Information for transplant programs and OPOs regarding 2019 Novel Coronavirus
PDF
United StatesOrgan Procurement and Transplantation Network (OPTN)
OPTN updates on candidate data during 2020 COVID-19 emergency. March 17th 2020
PDF
United StatesSouth - Transplantation Journal March Update
United StatesUNOS
Member information regarding COVID-19
News and updates for organ procurement organizations and transplant programs
Website
United StatesWest Coast - Transplantation Journal March Update
Oceania
AustraliaAustralian Government
Coronavirus information - Australia
Website
AustraliaDepartment of Health
Help and information Coronavirus (COVID-19) health alert
Website
AustraliaDepartment of health
Latest news
Website
AustraliaTransplantation Journal March Update
New ZealandThe New Zealand Government
Updates on COVID-19
New ZealandTransplantation Journal March Update

Publications

Transplantation Journal - The Impact of COVID-19 on the state of clinical and laboratory research globally in transplantation in May 2020
The impact of the COVID-19 pandemic is very wide and occupies almost every aspect of life across the world with the wave of direct health impacts cutting across each nation at different paces. The impact on the economies of all countries has been dramatic and has yet to become fully apparent. The effect of the pandemic on the health of transplant patients has been extensive with data published across a number of journals from both single centres and regional and national databases. It is becoming clear that transplant patients are more likely to catch SARSCov2 and when infected have a much increased mortality risk. Impact on clinical services, through reduction in ICU bed availability and decreased deceased organ donors, as well as diversion of clinical staff and other resources from transplantation, has led to dramatic decreases in clinical transplant activity. We have documented these impacts through the pages of Transplantation and through the COVID-19 Transplantation map established with the cooperation of The Transplantation Society (1,2). What has not yet been documented to any degree so far, is the impact on clinical and basic laboratory research in Transplantation. This round up of experiences from around the world shows substantial closure and diversion of effort from Transplantation research both in the clinic and in the laboratory with a future that is uncertain. Some countries and some centres have been more impacted than others. We hope by illuminating this feature of the pandemic we can assist in resuscitating research in our field as soon as compatible with the phases of the pandemic in each country.
Transplantation Journal - COVID WORLD ROUNDUP - April 2020

Mortality rates in Transplant recipients infected with SARSCov2 and diagnosed as having COVID-19. April 2020

There has been a global assumption that transplant recipients would be particularly endangered by the current pandemic of Coronovirus. Data have however been quite sparse and the ability to create a global picture has been limited.  Case reports are now giving way to small case series in the literature. The Transplantation Journal has collected the following data from correspondents from around the world and offers it as a very limited and highly flawed view of what might be happening.
Data from New York centres has been supplied from New York and are presented separately as they provide the most comprehensive view of the increased risk of death for transplant recipients across the spectrum of organ transplant types. The story of a widespread tragedy in the field of Transplantation is not underestimating the current data. Careful inspection of the data could be seen to show two features:

  1. High mortality rates in the range of 15-30% for transplant recipients in the countries and regions with high incidences and high mortality rates in the general populations.
  1. Low incidence and no mortality for transplant recipients in low incidence countries, suggesting that transplant recipients may have heeded well the messages to isolate themselves from the virus.

Country

COVID pos

alive In ICU

Dead

Mongolia

0

0

0

New Zealand

0

0

0

India (5 States)

1

0

0

Denmark

2

0

1

Singapore

0

0

0

Hong Kong

1

0

0

Brazil

27

3

7

Korea

2

0

0

Australia

3

0

0

USA

9

1

0

Italy

20

4

5

Strasbourg

48

10

9

London

7

4

1

Totals

120

22

23

(All data reports above are at the time of reporting in April)

 

Transplantation Journal - Global Transplantation Covid Report March 2020

This report was published in Transplantation:
April 1, 2020 - Volume Online First - Issue - doi: 10.1097/TP.0000000000003258

The COVID 19 pandemic has hit the entire world in an almost unprecedented way. The crisis has spread rapidly, disease burden and casualties continue to rise, and the impact of the crisis is spreading through developing countries. Social distancing, travel restrictions, and intensified testing have improved the rate of rise in new cases in some regions, however, it remains unclear when normality will return. Mechanisms of the disease remain largely unclear; treatment, if available, is mostly supportive. As during times of war, the challenges of the Coronavirus crisis change our views in almost any aspect.
Science - COVID-19
Coronavirus: Research, Commentary, and News
The Science journals are striving to provide the best and most timely research, analysis, and news coverage of COVID-19 and the coronavirus that causes it. All content is free to access. Science's COVID-19 reporting is supported by the Pulitzer Center.
The New England Journal of Medicine - COVID-19
A collection of articles and other resources on the Coronavirus (Covid-19) outbreak, including clinical reports, management guidelines, and commentary.
View Coronona Virus Dedicated page

Highlighted Articles:

April 25 - Letter to the Editor - Covid-19 and Kidney Transplantation
View Article

The Lancet - COVID-19
To assist health workers and researchers working under challenging conditions to bring this outbreak to a close, The Lancet has created a Coronavirus Resource Centre. This resource brings together new 2019 novel coronavirus disease (COVID-19) content from across The Lancet journals as it is published. All of our COVID-19 content is free to access.
Other Publications
PublicationAmerican Journal of Transplantation

Highlighted Articles:

May 5 - PERSONAL VIEWPOINT - Utilization of deceased donors during a pandemic: An argument against using SARS‐CoV‐2 positive donors
View Article

May 12 - PERSONAL VIEWPOINT - Use of SARS‐CoV‐2 infected deceased organ donors: Should we always “just say no?”
View Article

PublicationNew England Journal of Medicine
A collection of articles and other resources on the Coronavirus (Covid-19) outbreak, including clinical reports, management guidelines, and commentary.
View Coronona Virus Dedicated page

Highlighted Articles:

April 25 - Letter to the Editor - Covid-19 and Kidney Transplantation
View Article

Website
PublicationAmerican Society for Clinical Investigation - COVID-19 article collection

Highlighted Article: Kidney diseases in the time of COVID-19: major challenges to patient care
View Article

Website
PublicationAnnals of Internal MedicineWebsite
PublicationCA - A Cancer Journal for CliniciansWebsite
PublicationEuropean Heart JournalWebsite
PublicationEuropean UrologyWebsite
PublicationJAMA Internal MedicineWebsite
PublicationJournal of HepatologyWebsite
PublicationNature Reviews CancerWebsite
PublicationNature Reviews GeneticsWebsite
PublicationPhysiological ReviewsWebsite
PublicationScience Translational MedicineWebsite
PublicationThe Lancet Gastroenterology & Hepatology

Highlighted Article: COVID-19 in long-term liver transplant patients: preliminary experience from an Italian transplant centre in Lombardy
View Article

Website
PublicationTrends in ImmunologyWebsite

Latest Videos

May 1 - The Trinity of COVID-19: Immunity, Inflammation and Intervention | Assoc Prof Paul MacAry
The multi-society collaboration COVID-19: Organ Donation and Transplantation Town Hall webinars are now available on demand.
American Medical Association Daily updates
Click for Daily Updated VIdeos
American Medical AssociationApril 20 UpdatePlay Video
American Medical AssociationApril 17 UpdatePlay Video
American Medical AssociationApril 16 UpdatePlay Video
American Medical AssociationApril 15 UpdatePlay Video
American Medical AssociationApril 14 UpdatePlay Video
American Medical AssociationApril 13 UpdatePlay Video
American Medical AssociationApril 10 UpdatePlay Video
American Medical AssociationApril 9 - COVID-19: AMA’s National Physician Townhall
The American Medical Association invites you to a live conversation with AMA President Patrice A. Harris, MD, MA, and a panel of AMA health care experts on challenges and concerns facing physicians during this unprecedented COVID-19 crisis.
Play Video
American Medical AssociationApril 8 UpdatePlay Video
American Medical AssociationApril 7 - National Address from the American Medical Association President PresidentPlay Video
American Medical AssociationApril 7 UpdatePlay Video
American Medical AssociationApril 6 UpdatePlay Video
American Medical AssociationApril 3 UpdatePlay Video
American Medical AssociationApril 2 UpdatePlay Video
American Medical AssociationApril 2 - Prioritizing Equity: Experience of Physicians of Color &COVID-19Play Video
American Medical AssociationApril 1 - UpdatePlay Video
American Medical AssociationMarch 31 - UpdatePlay Video
American Medical AssociationMarch 30 - UpdatePlay Video
American Medical AssociationMarch 27 - UpdatePlay Video
American Medical AssociationMarch 26 - UpdatePlay Video
American Medical AssociationMarch 25 - UpdatePlay Video

April 14, 2020 - How to ensure unrelated donor grafts & CAR-T cell products during the Corona pandemic
Details and Play Video
This webinar organized by EBMT and WMDA was aimed at transplant center physicians, search coordinators, and transplant coordinators, who are coordinating unrelated transplants for their patients. Visit the EBMT website for more information: https://www.ebmt.org/covid-19-webinars

April 7, 2020 - Heart Transplantation in a Viral Pandemic
Details
A webinar specifically for the cardiac transplant community to share current understanding and strategies in the global COVID-19 emergency. Chetan Patel, MD / Medical Director, Cardiac Transplant Program, Duke University / Andreas Zuckermann, MD / Director, Cardiac Transplantation, Medical University of Vienna - AKH Vienna / Scott Silvestry, MD / Surgical Director, Thoracic Transplant Programs, AdventHealth Orlando / David Klassen, MD / Chief Medical Officer, UNOS. Use the link below to register to view the recording.

April 6, 2020 - JAMA COVID-19 Clinical Update.
Questions about testing, chloroquine toxicity, duration of immunity and reinfection, and what to expect next are gripping the US as the novel coronavirus spreads. Preeti Malani MD, Professor of Medicine and Chief Health Officer at the University of Michigan discusses recent developments in a live conversation with JAMA Editor Howard Bauchner. Originally streamed on April 6, 2020.
Click to play video

CME for watching this livestream will be available here: https://ja.ma/covidqa Coronavirus Resource page from the JAMA Network: https://ja.ma/covidyt

1:55 Overview of Dr Bauchner's interview with Dr Malani
2:01 Case-fatality rate
4:50 CDC’s changing views on masks - what should we make of the change?
7:45 Should or shouldn’t I wear a mask?
8:46 Medical workers
9:49 PCR tests, should we trust the accuracy?
11:29 Can you become reinfected?
13:18 Serology and the likelihood of antibody testing (who is immune/ has antibodies to the virus) and being able to go to work if proven immune.
16:01 How long can we assume we are immune for, given the data we have.
17:36 How is COVID-19 spreading? Droplets versus aerolization spread. Coughs and sneezes or just through the air?
21:00 How long does the coronavirus live on packages, newspapers, groceries?
23:50 Infected tiger at the Bronx Zoo. Animal responses to COVID
24:52 Discussion on study of viral load found in stool/ 14 day quarantine still to be trusted?
29:51 Health care workers
33:04 What will work for treatment of COVID. Hydroxychloroquine discussion. Remdesivir trials. 35:25 Social distancing, how long will it go on?

April 1, 2020 - Treatment of Transplant Patients with COVID-19 Infections (A. Osama Gaber, MD)

March 25, 2020: Johns Hopkins School of Advanced International Studies - The Coronavirus Crisis: Responses in China, Italy, and the United States.

Latest News

More News

Latest Tweets

TTS

TTS

Join IRTA and TTS in the upcoming webinar on "Pediatric Intestinal Failure &Transplant: Updates in Patient Care" 🗓 Monday, July 20, 9 am EDT / 3 pm CEST ➡ Register here: bit.ly/3gPdGK5

Read more

TTS

TTS

ICYMI - We've created a #COVID19 dashboard that connects you to several global and regional resources, as well as to interactive maps, publications and webinars to keep you informed. Find it here 👉 tts.org/covid-19 #DesignedToEmpower #Coronavirus #TTS2020

Read more

TTS

TTS

📖 Don't miss this week's top #COVID19 publications selected by the TTS Education Committee. Find this week's selections here 👉 bit.ly/2ZP3dax #DesignedToEmpower #TTS2020 #Coronavirus #LiverTransplantation #SocialDistancing

Read more

TTS

TTS

#TTS2020 virtual SOTA and Workshop session presentations are now available online by topic track! Begin building your personal congress agenda today! More info here 👉 tts2020.org/program/progra… #DesignedToEmpower #TTS2020 #VirtualTTS

Read more

Social

Contact

Staff Directory
+1-514-874-1717
This email address is being protected from spambots. You need JavaScript enabled to view it.

Address

The Transplantation Society
International Headquarters
505 Boulevard René-Lévesque Ouest
Suite 1401
Montréal, QC, H2Z 1Y7
Canada